J&J Sees 82% Surge in Q1 Sales of Yuhan's LECLAZA Combination Therapy
Johnson & Johnson Announces First Quarter Earnings
LECLAZA (ingredient: lazertinib), a lung cancer treatment developed by Yuhan Corporation and licensed out, is strengthening its presence in the global market, particularly through combination therapy with RYBREVANT (ingredient: amivantamab).
According to the industry on April 15, Johnson & Johnson’s (J&J) revenue from the LECLAZA and RYBREVANT combination therapy in the first quarter of this year soared by 82% year-on-year to 257 million dollars (approximately 378.6 billion won). Compared to the previous quarter, revenue increased by 19%.
By region, sales in the United States reached 175 million dollars (approximately 257.8 billion won), up 55.1% from the same period last year. Overseas sales grew by more than 100% year-on-year to 82 million dollars (approximately 120.8 billion won).
The LECLAZA and RYBREVANT combination therapy was cited as one of the key products driving growth in J&J's oncology segment. In its earnings announcement, J&J stated that the LECLAZA combination therapy, along with DARZALEX (ingredient: daratumumab) and CARVYKTI (ingredient: ciltacabtagene autoleucel), led the growth of its innovative medicines division.
J&J’s total first-quarter revenue was 24.062 billion dollars (approximately 35.482 trillion won), up 9.9% from the same period last year. The innovative medicines division posted 15.426 billion dollars (22.7471 trillion won), an increase of 11.2% year-on-year.
LECLAZA is a third-generation EGFR-targeted anticancer drug independently developed by Yuhan Corporation. In 2018, Yuhan licensed the drug out to Janssen, a J&J affiliate. Under the terms of the agreement, Yuhan receives royalties linked to J&J’s global sales, meaning that the growth in combination therapy revenue directly impacts Yuhan’s earnings.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The LECLAZA and RYBREVANT combination therapy received U.S. Food and Drug Administration (FDA) approval in 2024 and is now moving into full-scale global commercialization.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.